Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
06 Septiembre 2022 - 6:00AM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that it will participate virtually at the H.C. Wainwright 24th
Annual Global Investment Conference, and its presentation will be
available beginning at 7:00 a.m. ET on September 12, 2022.
The on-demand webcast of the presentation may be accessed in the
Investors section of the Company’s website at
www.concertpharma.com. A replay of the webcast will be available on
Concert’s website for two weeks following the presentation.
About Concert
Concert Pharmaceuticals is a late-stage clinical
biopharmaceutical company that is developing CTP-543, a novel oral
JAK1/2 inhibitor. Concert has successfully completed two Phase 3
trials with CTP-543 in adults with alopecia areata, a serious
autoimmune dermatological condition. The Company is also evaluating
the use of CTP-543 in other indications and assessing a number of
earlier-stage pipeline candidates. For more information, please
visit www.concertpharma.com or follow us on Twitter at
@ConcertPharma or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220906005117/en/
Justine Koenigsberg (781) 674-5284 ir@concertpharma.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Concert Pharmaceuticals Inc (NASDAQ): 0 recent articles
Más de Concert Pharmaceuticals Inc Artículos de Noticias